Ionis Pharmaceuticals Inc (IONS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $44.82 (-4.13%), Market cap $12.10B, 52-week low–high $29.74 ~ $86.50.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment
Financial statements, price targets, institutional (13F) holdings and related news for Ionis Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Ionis Pharmaceuticals Inc trades at $44.82 (-4.13%). Real-time quotes and charts are available on BlackAll Trade.
Ionis Pharmaceuticals Inc has a market cap of about $12.10B.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with fam